Type 1 Diabetes
Autoimmune destruction of pancreatic beta cells causing insulin dependence. MSC therapy modulates autoimmunity and supports residual beta-cell preservation.
Type 1 diabetes mellitus is an autoimmune disease in which cytotoxic T cells destroy insulin-producing beta cells in the pancreatic islets of Langerhans. The result is absolute insulin deficiency requiring lifelong insulin replacement. T1D onset typically occurs in childhood or adolescence but can develop at any age.
Despite advances in continuous glucose monitoring and insulin delivery technology, T1D remains a daily burden with risks of life-threatening hypoglycemia, ketoacidosis, and long-term microvascular and macrovascular complications. The autoimmune process continues to destroy residual beta cells even after diagnosis, making early immunological intervention critical.
MSC therapy is being evaluated in T1D for two distinct goals: preserving residual beta-cell function around the time of diagnosis (honeymoon phase), and modulating chronic autoimmunity to slow the progression of long-standing T1D.
MSCs are potent modulators of the T-cell-mediated autoimmune response targeting beta cells. They suppress autoreactive CD8+ T-cell activity, expand Treg populations that enforce immune self-tolerance, and reduce insulitis (pancreatic islet inflammation). In animal models of T1D, MSC infusion has demonstrated preservation of beta-cell mass, normalization of glucose, and reduced anti-islet antibody titers.
Human clinical trials — including a randomized controlled trial published in JAMA — have reported that MSC infusion in newly diagnosed T1D patients preserved C-peptide secretion (a measure of residual beta-cell function) and reduced insulin requirements over 24 months compared with placebo. Anti-islet antibody levels were also reduced in treated patients.
True Regen coordinates endocrinology records review, C-peptide testing, anti-GAD antibody levels, and HbA1c history to evaluate each patient and design an individualized protocol in collaboration with Regen Cord.
- Preservation of residual beta-cell function (C-peptide)
- Reduced daily insulin requirements
- Improved HbA1c and time-in-range
- Reduced anti-islet autoantibody titers
- Fewer hypoglycemic episodes
Individual results vary. All patients undergo full medical evaluation prior to treatment.
ISO/cGMP-Certified Lab
Every infusion is manufactured under pharmaceutical-grade controls. You receive a batch-specific Certificate of Analysis before treatment.
High-Dose MSC Protocol
Wharton's jelly umbilical-cord MSCs — younger, more potent, and more consistent than cells from the patient's own body.
Dedicated Coordinator
One person manages every detail of your journey — from your first inquiry through your 12-month follow-up.
Ready to take the next step?
One conversation could change everything.
Your dedicated coordinator will review your case and walk you through the entire process — with zero pressure, zero cost, and zero commitment.